cyclic heptapeptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-04-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Synthetic cyclic heptapeptide |
| Molecular mass | Approximately 1024 g/mol | Depends on counter-ion content |
| Appearance | White to off-white powder | Commonly supplied as a lyophilised solid |
| Solubility | Freely soluble in water | Also dissolves in common aqueous buffers |
| Typical storage | -20 degrees Celsius, desiccated | Protect from light and repeated freeze-thaw |
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
=== Sonic spray ionization === Sonic spray ionization is method for creating ions from a liquid solution, for example, a mixture of methanol and water. A pneumatic nebulizer is used to turn the solution into a supersonic spray of small droplets. Ions are formed when the solvent evaporates and the statistically unbalanced charge distribution on the droplets leads to a net charge and complete desolvation results in the formation of ions. Sonic spray ionization is used to analyze small organic molecules and drugs and can analyze large molecules when an electric field is applied to the capillary to help increase the charge density and generate multiple charged ions of proteins. Sonic spray ionization has been coupled with high performance liquid chromatography for the analysis of drugs. Oligonucleotides have been studied with this method. SSI has been used in a manner similar to desorption electrospray ionization for ambient ionization and has been coupled with thin-layer chromatography in this manner.
Inverter compressors not only optimizes cooling but is also superior in terms of durability and energy efficiency. A device consumes maximum energy and undergoes maximum wear and tear when it switches itself on. As an inverter compressor never switches itself off and instead runs on varying speed, it minimizes wear and tear and energy usage. LG played a significant role in improving inverter compressors as we know it by reducing the friction points in the compressor and thus introducing Linear Inverter Compressors. Conventionally, all domestic refrigerators use a reciprocating drive which is connected to the piston. But in a linear inverter compressor, the piston which is a permanent magnet is suspended between two electromagnets. The AC changes the magnetic poles of the electromagnet, which results in the push and pull that compresses the refrigerant. LG claims that this helps reduce energy consumption by 32% and noise by 25% compared to their conventional compressors.
The U.S. Army Special Forces traces its roots as the Army's premier proponent of unconventional warfare from purpose-formed special operations units like the Alamo Scouts, Philippine guerrillas, First Special Service Force, and the Operational Groups (OGs) of the Office of Strategic Services. Although the OSS was not an Army organization, many Army personnel were assigned to the OSS and later used their experiences to influence the forming of Special Forces. During the Korean War, individuals such as former Philippine guerrilla commanders Col. Wendell Fertig and Lt. Col. Russell W. Volckmann used their wartime experience to formulate the doctrine of unconventional warfare that became the cornerstone of the Special Forces. In 1951, Major General Robert A. McClure chose former OSS member Colonel Aaron Bank as Operations Branch Chief of the Special Operations Division of the Psychological Warfare Staff (OCPW) in the Pentagon. In June 1952, the 10th Special Forces Group (Airborne) was formed under Col. Aaron Bank, soon after the establishment of the Psychological Warfare School, which ultimately became today's John F. Kennedy Special Warfare Center and School. The 10th Special Forces Group (Airborne) was split, with the cadre that kept the designation 10th SFG deployed to Bad Tölz, Germany, in September 1953. The remaining cadre at Fort Bragg formed the 77th Special Forces Group, which in May 1960 was reorganized and designated as today's 7th Special Forces Group.
The United States Army uses various personnel management systems to classify soldiers in different specialties which they receive specialized and formal training on once they have successfully completed Basic Combat Training (BCT). Enlisted soldiers are categorized by their assigned job called a Military Occupational Specialty (MOS). MOS are labeled with a short alphanumerical code called a military occupational core specialty code (MOSC), which consists of a two-digit number appended by a Latin letter. Related MOSs are grouped together by Career Management Fields (CMF). For example, an enlisted soldier with MOSC 11B works as an infantryman (his MOS), and is part of CMF 11 (the CMF for infantry). Commissioned officers are classified by their area of concentration, or AOC. Just like enlisted MOSCs, AOCs are two digits plus a letter. Related AOCs are grouped together by specific branch of the Army or by broader in scope functional areas (FA). Typically, an officer will start in an AOC of a specific branch and move up to an FA AOC. Warrant officers are classified by warrant officer military occupational specialty, or WOMOS. Codes consists of three digits plus a letter. Related WOMOS are grouped together by Army branch. The Army is currently restructuring its personnel management systems, as of 2019. Changes took place in 2004 and continued into 2013. Changes include deleting obsolete jobs, merging redundant jobs, and using common numbers for both enlisted CMFs and officer AOCs (e.g. "35" is military intelligence for both officers and enlisted).
The term packing fraction was defined by Aston as the difference of the measured mass M and the nearest integer mass I (then based on the oxygen-16 mass scale) divided by the quantity comprising the mass number multiplied by ten thousand:
Sources: en.wikipedia.org
== History == Methaqualone was first synthesized in India in 1951 by Indra Kishore Kacker and Syed Husain Zaheer, who were conducting research on finding new antimalarial medications. In 1962, methaqualone was patented in the United States by Wallace and Tiernan. By 1965, it was the most commonly prescribed sedative in Britain, where it has been sold legally under the names Malsed, Malsedin, and Renoval. In 1965, a methaqualone/antihistamine combination was sold as the sedative drug Mandrax in Europe, by Roussel Laboratories (now part of Sanofi S.A.). In 1972, it was the sixth-bestselling sedative in the US, where it was legal under the brand name Quaalude. Sold in the United States under the brand name Quaalude, methaqualone was moved to Schedule I in 1984 after prescription controls failed to curb diversion. Quaalude in the United States was originally manufactured in 1965 by the pharmaceutical firm William H. Rorer, Inc., based in Fort Washington, Pennsylvania. The drug name "Quaalude" is a portmanteau, combining the words "quiet interlude" and shared a stylistic reference to another drug marketed by the firm, Maalox. In 1978, Rorer sold the rights to manufacture Quaalude to the Lemmon Company of Sellersville, Pennsylvania. At that time, Rorer chairman John Eckman commented on Quaalude's bad reputation stemming from illegal manufacture and use of methaqualone, and illegal sale and use of legally prescribed Quaalude: "Quaalude accounted for less than 2% of our sales, but created 98% of our headaches." Both companies still regarded Quaalude as an excellent sleeping drug.
The far-right political party Britain First received a gold checkmark, signifying that it was a business, while its leader, Paul Golding, has a blue checkmark. According to researcher Nima Owji, Twitter will allow users who have received Twitter Blue for free to cancel their subscription.
Loss of perivascular collagen occurs; it is thought that this is due to the degradative enzymes released by extravasating leukocytes, such that the collagen and other connective tissue fibers surrounding blood vessels in the area dissolve. When this occurs the gums will appear bright red and either bulbous or rounded, from all the excess fluid building up in the infected area. The initial lesion appears within two to four days of gingival tissue being subjected to plaque accumulation. When not generated through clinical experimentation, the initial lesion may not appear at all, and instead, a detectable infiltrate similar to that of the early lesion, explained below, appears.
Abdomen and obliques (belly) Crunch (i) Leg raise (c) Russian twist (c) Sit-up (c) Biceps (front of upper arms) Biceps curl (i) Pull ups with a supinated grip Calves Calf raise (i) Deltoids (shoulders) Front raise (i) Head stand into Handstand push-up (c) Lateral raise (i) Military press (c) Rear delt raise (i) Shoulder press (c) Upright row (c) Forearms Wrist curl (i) Wrist extension (i) Hamstrings (back of thighs) Deadlift (c) Frog jumping (i) Good-morning (exercise) (c) Leg curl (i) Squat (c) Lats and trapezius (back) Bent-over row (c) Chin-up (c) Pulldown (c) Pullup (c) Seated row (c) Shoulder shrug (i) Supine row (c) Lower back Deadlift (c) Good-morning (exercise) (c) Hyperextension (c) Pectorals (chest) Bench press (c) Chest fly (i) Dips (c) Machine fly (i) Push-up (c) Pelvis Vaginal weightlifting Quadriceps (front of thighs) Frog Jumping (i) Leg extension (i) Leg press (c) Lunge (c) Squat (c) Triceps (back of upper arms) Close-grip bench press (c) Dips (c) Push-down (exercise) (i) Lying triceps extensions (i)
Sources: en.wikipedia.org
== Habitat and range == C. brunneus are found in Europe, north Africa, and temperate Asia. They prefer dry habitats. They are present in higher numbers in heathland areas compared to agricultural areas. This can be explained by the difference in sward height in the two areas. C. brunneus prefer habitats with sward heights of 100 to 200 mm and fine leaved grass species. In fact a positive correlation between C. brunneus and both Agrostis species and Festuca species exists. Fine leaved grass species and taller sward heights occur more commonly in heathlands where less human alteration of the land occurs compared to agricultural sites. Sward height also influences abundance. A greater number of C. brunneus are found in taller swards although some scientific literature suggests C. brunneus thrives in wastelands. Vertebrate grazing also influences C. brunneus density by directly influencing sward height. Ungrazed areas have higher densities of C. brunneus than grazed areas. Vertebrate grazing is thought to alter plant hormones two of which are known to effect fecundity, abscisic acid, and gibberellins. Additionally grazing results in the production of proteinase inhibitors in plants and the alteration of nitrogen levels. In areas that experience less vertebrate grazing C. brunneus have increased rates of development, higher adult weights, and increased fecundity.
== Covalently modulated enzymes == Here, the active and inactive form of the enzymes are altered due to covalent modification of their structures which is catalysed by other enzymes. This type of regulation consists of the addition or elimination of some molecules which can be attached to the enzyme protein. The most important groups that work as modifiers are phosphate, methyl, uridine, adenine and adenosine diphosphate ribosyl. These groups are joined to or eliminated from the protein by other enzymes. The most remarkable covalent modification is phosphorylation. Serine, Threonine and Tyrosine are common amino acids that participate in covalent modifications and are used to control enzyme’s catalytic activities. Kinase and phosphatases are commonly known enzymes that affect these modifications, which result in shifting of conformational states of the binding affinity to substrate.
In December 2018, the Democratic National Committee (DNC) announced the preliminary schedule for 12 official DNC-sanctioned debates, set to begin in June 2019, with six in 2019 and the remaining six during the first four months of 2020. During the July and September debates, commentators described Sanders and Elizabeth Warren as having a "non-aggression pact", staking out similar progressive positions in contrast to the more conservative candidates. In the October 15 debate, his first appearance since his heart attack, debate coach Todd Graham gave Sanders's performance an A, his highest rating of all the candidates. CNN hosted the first 2020 debate in January with six candidates remaining. Co-moderator Abby Phillip questioned Sanders and Warren about an allegation Warren had made that he had privately told her that a woman could not defeat Donald Trump. Phillip asked Sanders, "Senator Sanders, CNN reported yesterday, and Senator Warren confirmed in a statement, that in 2018 you told her that you did not believe that a woman could win the election. Why did you say that?" Ignoring Sanders's strong denial, Phillip asked Warren, "What did you think when Bernie Sanders told you that a woman couldn't become president?" In an interview after the debate, Sanders called it ludicrous to believe that he would doubt a woman's ability to win the presidency and noted that a woman already had won the national popular vote, saying, "After all, Hillary Clinton beat Donald Trump by 3 million votes in 2016."
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.
It is shorter than the native hormone and carries a cyclic constraint that improves stability. These changes raise receptor potency and slow breakdown relative to the naturally occurring peptide.
Published accounts date its development to the 1980s, when researchers were generating analogues of melanocyte-stimulating hormone. That work aimed to produce more stable compounds for studying pigmentation biology.
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.